Psoriasis vulgaris (PV) is a chronic inflammatory skin disease, which is characterized by the abnormal proliferation and apoptosis of keratinocytes. Previous studies have demonstrated that transcription factor Wilms' tumor 1 (WT1) is involved in a number of pathophysiological processes, including organ development, tumorigenesis and cell proliferation. However, the role of WT1 in PV remains unclear. In the present study, WT1 expression was analyzed by reverse transcription-quantitative polymerase chain reaction and western blot analyses. WT1 was stably overexpressed or inhibited in HaCaT cells using Lipofectamine ® 2000, and cell proliferation and apoptosis were determined using a Cell Counting Kit-8 or Fluorescein Isothiocyanate Annexin V Apoptosis Detection kit II, respectively. We demonstrated that compared with normal controls, the mRNA and protein expression levels of WT1 were significantly increased in non-lesional skins (human, P<0.0001 and P= 0.0291, respectively; mouse, P=0.0020 and P=0.0150, respectively) and lesional skins (human, P<0.0001 and P=0.0060, respectively; mouse, P=0.0010 and P=0.0172, respectively) of patients with PV, in addition to the imiquimod (IMQ)-induced psoriasis-like mouse model. WT1 mRNA and protein expression levels in lesional skins were slightly increased compared with those in non-lesional skins from patients with psoriasis (P= 0.2510 and P=0.1690, respectively) and IMQ-treated mice (P=0.9590 and P=0.2552, respectively), although there were no statistical differences. Knockdown of WT1 inhibited the proliferation of HaCaT cells [day (D)4, P=0.0454; D5, P=0.0021] and promoted their apoptosis (P=0.0007), while overexpressing WT1 exhibited the opposite effects (proliferation D3, P= 0.0216; D4, P=0.0356; D5, P=0.0188; apoptosis, P=0.0003). Furthermore, it was identified that the inflammatory cytokines interleukin-17A (IL-17A), interferon-γ and IL-22 induced the overexpression of WT1 in HaCaT cells. The results of the present study suggested that inflammatory cytokine-induced WT1 overexpression may promote the formation of psoriatic skin lesions via regulation of the proliferation and apoptosis of keratinocytes.
Introduction
Psoriasis is a chronic inflammatory skin disease, which may severely impact the quality of life of patients and manifests as erythematous plaques covered with silvery-white scales (1) . Psoriatic lesions are characterized by epidermal hyperplasia with parakeratosis, loss of the granular layer, acanthosis, aberrant differentiation, proliferation of keratinocytes and marked infiltration of immune cells into the dermis or epidermis (2) . The pathogenesis of psoriasis is complex, and the exact underlying mechanism of the factors involved remains elusive. The abnormal proliferation of keratinocytes is a key feature of psoriasis, which results in epidermal hyperplasia and the morphological characteristics of psoriasis (3) . It is widely accepted that the abnormal growth dynamics of keratinocytes are due to the dysregulation of cytokines and growth factors, which are secreted by infiltrated immune cells in the skin lesions (4, 5) . Among these, interferon-γ (IFN-γ), interleukin (IL)-17A and IL-22 have been demonstrated to be increased and to serve important roles in the development of the skin lesions observed in patients with psoriasis (6) (7) (8) (9) (10) . However, the molecular mechanisms involved in this process remain unclear.
The Wilms' tumor 1 (WT1) gene, which maps to chromosome 11p13 and contains 10 exons, encodes a DNA-binding transcription factor that is involved in the regulation of
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human cell growth and differentiation (11) . This gene locus is frequently mutated in patients with Wilms' tumor. In addition, alterations in this gene have been identified in a variety of cancer types, including breast cancer, renal cell cancer, ovarian cancer, lung cancer, melanoma and acute leukemia (12) (13) (14) (15) (16) (17) (18) . In these types of cancer, WT1 acts as either an oncogene or a tumor suppressor gene, depending on the different cellular characteristics (19) (20) (21) . However, to the best of our knowledge, there have been no previous studies focusing on the expression and role of WT1 in the formation of psoriatic skin lesions. The present study detected the expression of WT1 in the non-lesional skins and skin lesions from patients with psoriasis vulgaris (PV) and an imiquimod (IMQ)-induced psoriasis-like mouse model. The effect of WT1 on the proliferation and apoptosis of keratinocytes was subsequently investigated. It was revealed that WT1 expression was significantly increased in non-lesional skin tissues and psoriatic skin lesions. Overexpressing WT1 promoted keratinocyte proliferation and inhibited apoptosis. In addition, certain inflammatory cytokines upregulated WT1 in keratinocytes. These findings indicated that WT1 may serve an important role in the formation of skin lesions associated with PV.
Materials and methods
Human subjects. A total of 20 psoriatic patients who were diagnosed with PV by pathological examination were recruited from outpatient clinics at the Second Xiangya Hospital of Central South University (Changsha, China). Psoriasis disease activity was assessed using psoriasis area and severity index (PASI) scores (22) , and blood samples and lesional skins were collected. Non-lesional skin tissues were obtained from 10 of the patients simultaneously. Patient information is presented in Table I . Blood samples were collected from 20 sex-and age-matched healthy controls who were recruited from the medical staff at the Second Xiangya Hospital. Normal skin tissues were obtained from the outpatient operating room at the Department of Dermatology at the Second Xiangya Hospital. The information of all healthy controls is presented in Table II . The present study was approved by the Ethics Committee of the Second Xiangya Hospital of Central South University. Written informed consent was obtained from all subjects.
Assessment of PASI scores. For determining the severity and extent of psoriasis, PASI scoring was used (22, 23) . In the four regions of the body, namely the head (h), upper extremities (u), lower extremities (l) and torso (t), the characteristics of the disease, including erythema (E), infiltration (I) and desquamation (D), were evaluated with a score of 1-4, and the involved area (A) of psoriatic lesions was evaluated with a score of 1-6 (Table III) . PASI total scores ranges between 0 and 72. Higher scores indicate greater psoriasis severity. The formula used to calculate the total PASI score is as follows: PASI= (E h +I h +D h )xA h x0.1+(E u +I u +D u ) xA u x0.2+(E t +I t +D t )xA t x0.3+(E l +I l +D l )xA l x0.4 IMQ-induced psoriasis-like mouse model. Female BALB/c mice (age, 6-8 weeks; 19.0-20.5 g) were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China). All mice were maintained in specific pathogen-free conditions (20-24˚C; relative humidity, 50-55%; 12 h light/dark cycle) with free access to food and water. The IMQ-induced psoriasis-like mouse model was established as previously described (24) . The mice were treated with a daily topical dose of 62.5 mg 5% IMQ cream (cat. no. H20030128; Sichuan Med-Shine Pharmaceutical Co., Ltd., Chengdu, China) on their shaved backs for 7 consecutive days. The control mice were treated with the same dose of vehicle cream. All procedures were approved and supervised by the Animal Care and Use Committee of the Second Xiangya Medical School of Central South University.
Cell isolation and culture. Peripheral blood mononuclear cells (PBMCs) were separated from the peripheral blood of healthy controls and patients with psoriasis by density gradient centrifugation at 18˚C and 600 x g for 30 min (GE Healthcare, Chicago, IL, USA). The cells were cultured in RPMI 1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; HyClone; GE Healthcare Life Sciences, Logan, UT, USA) at 37˚C in 5% CO 2 , or collected directly for subsequent experiments. HaCaT cells (cat no. BNCC101683; BeNa Culture Collection, Beijing, China), which were stored in liquid nitrogen, were revived and cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS at 37˚C in 5% CO 2 . The medium was refreshed every 2 days and the cells were subcultured when 90% confluence was reached.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from the cells or skin tissues using TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.), and a NanoDrop spectrophotometer (ND-2000; Thermo Fisher Scientific, Inc.) was used for RNA quality control. The mRNA was reverse-transcribed using a PrimeScript ® RT reagent kit with gDNA Eraser (Takara Biotechnology Co., Ltd., Dalian, China). Each test used 1 µg total RNA and was performed according to the manufacturer's protocol. qPCR was subsequently performed using the SYBR Premix Ex Taq II (Tli RnaseH Plus; Takara Biotechnology Co., Ltd.) using a LightCycler ® 96 (Roche Diagnostics, Basel, Switzerland) thermocycler. The thermocycling conditions were as follows: Initial denaturation at 95˚C for 30 sec, followed by 45 cycles of 95˚C for 5 sec and 60˚C for 20 sec, and a final extension (95˚C for 1 sec, 65˚C for 15 sec and 95˚C for 1 sec). The relative expression of the target genes was calculated using the 2 -ΔΔCq method (25) and normalized against the GAPDH internal control. Detailed information on the primers used is summarized in Table IV .
Western blot analysis. The cells or skin tissues were lysed in radioimmunoprecipitation assay buffer supplemented with protease and phosphatase inhibitors (Beyotime Institute of Biotechnology, Haimen, China). The proteins were quantified using a Bradford assay (Pierce; Thermo Fisher Scientific, Inc.) and 100 µg protein from each sample was loaded for 8% SDS-PAGE. Following the transfer of proteins onto a polyvinylidene fluoride membrane, the membrane was blocked with 5% skim milk in PBS with 0.1% Tween-20 at room temperature for 1 h. Rabbit anti-WT1 (1:1,000; cat no. ab89901;
Abcam, Cambridge, UK) and goat anti-GAPDH (1:2,000; cat no. ab9483; Abcam) primary antibodies were incubated with the membrane at 4˚C overnight. Horseradish peroxidase (HRP) goat anti-rabbit immunoglobulin (Ig)G (H+L) (1:5,000; cat no. AS014; ABclonal Biotech Co., Ltd., Woburn, MA, USA) and HRP donkey anti-goat IgG (H+L) (1:5,000; cat no. A00178; GenScript, Piscataway, NJ, USA) secondary antibodies were incubated at room temperature for 2 h. The data was analyzed using a GE-ImageQuant LAS 4000 mini (GE Healthcare). The quantification of WT1 was normalized against GAPDH by densitometric analysis with Image-Pro Plus 6.0 (Media Cybernetics, Inc., Rockville, MD, USA). The images were cropped for presentation.
Immunohistochemistry. Skin tissues were fixed in formalin at room temperature overnight and embedded in paraffin. The 6-µm-thick sections were stained with hematoxylin for 10 min, and then stained with eosin for 2 min at room temperature. For immunohistochemistry, the sections were stained with rabbit anti-WT1 (1:200; cat no. ab89901; Abcam) or rabbit anti-Ki67 polyclonal antibodies (1:100; cat no. ab15580; Abcam) at 4˚C overnight, according to the manufacturer's protocol. Image analysis was performed using a DMI 4000B microscope (magnification, x100) and Leica Qwin Std analysis software version 3 (both Leica Microsystems GmbH, Wetzlar, Germany).
Small interfering (si)RNA and plasmid transfection of HaCaT cells.
A total of 12 h prior to transfection, the HaCaT cells were seeded in a 6-well cell culture plate at 6x10 3 cells/well. The cells were transfected with 20 nM WT1 siRNA, 5 µg WT1 plasmid or their corresponding controls using Lipofectamine ® 2000 (Invitrogen, Thermo Fisher Scientific, Inc., USA) for 6 h in Opti-minimum essential medium (Opti-MEM; Gibco; and analyzed using FlowJo software version 10 (FlowJo LLC, Ashland, OR, USA).
Cytokine stimulation of HaCaT cells.
HaCaT cells were stimulated with 0, 10, 20 or 50 ng/ml IL-17A, IFN-γ or IL-22 (all PeproTech, Inc., Rocky Hill, NJ, USA). The cells were collected after 24 h for RT-qPCR analysis.
Statistical analysis. Data are presented as the mean ± standard error of the mean of at least three experiments. Statistical analysis was performed using GraphPad Prism 6.0 software (GraphPad Software, Inc., La Jolla, CA, USA) and P<0.05 was considered to indicate a statistically significant difference. The data were assessed for normality of distribution and a similar variance between groups. A two-tailed unpaired Student's t-test was used for comparisons between two groups and one-way analysis of variance with the corresponding post-hoc test (Bonferroni or Dunnett's) were used for the comparison of multiple groups. When the data were not normally distributed or there were not equal variances between two groups, a two-tailed Mann-Whitney U-test was used for statistical analysis. Correlation analysis was performed using a Spearman's r test.
Results

WT1 expression is elevated in non-lesional and lesional skins of patients with psoriasis and IMQ-induced psoriasis-like model mice.
To examine the role of WT1 in the pathogenesis of psoriasis, the mRNA expression level of WT1 was initially Table III . Psoriasis area and severity index evaluation criteria. 
F, forward; R, reverse; WT1, Wilms' tumor 1.
determined in 10 non-lesional skins and 20 lesional skins taken from patients with psoriasis and skin samples taken from 20 normal human controls using RT-qPCR. The results demonstrated that the mRNA expression of WT1 was significantly increased in non-lesional skins and lesional skins from patients with PV, compared with the normal controls ( Fig. 1A) . Similarly, the protein expression of WT1 in non-lesional skins and lesional skins from patients with PV was also increased compared with the normal controls ( Fig. 1B and C) . The results suggested that WT1 mRNA and protein expression levels in lesional skins were slightly increased compared with those in non-lesional skins from patients with psoriasis, although there were no statistical differences ( Fig. 1A-C) . Notably, the WT1 mRNA expression level in the psoriatic skin lesions was positively correlated with the PASI scores of the patients (Fig. 1D ). In addition, immunohistochemistry with anti-WT1 antibodies was used to detect the expression and location of WT1 in the skin tissues. It was confirmed that the expression of WT1 was primarily enhanced in the epidermis of the psoriatic skin lesions (Fig. 1E ). However, no significant differences were observed in the mRNA and protein expression levels of WT1 in the PBMCs of patients with PV compared with the normal controls ( Fig. 1F-H) . Furthermore, the present study detected the WT1 expression in an IMQ-induced psoriasis-like mouse model, which closely resembles the human psoriasis phenotype, according to a previously published study (24) . IMQ cream was applied to the shaved backs of BALB/c mice for 7 consecutive days to establish this model. As expected, the IMQ-treated mice developed typical psoriasis-like lesions with evident clinical and histological alterations ( Fig. 2A and B) . The results demonstrated that the expression of Ki67, a marker exclusively associated with cell proliferation, was significantly increased in the IMQ-treated mice compared with the controls, which indicated that the excessive proliferation of keratinocytes was induced by the IMQ (Fig. 2C) . Consistent with the results of the human samples, the mice exposed to IMQ expressed significantly higher levels of WT1 mRNA and protein in their non-lesional skins and skin lesions compared with the vehicle-exposed mice (Fig. 2D-G) .
Overexpressing WT1 in keratinocytes promotes proliferation and inhibits apoptosis. Abnormal proliferation and apoptosis of keratinocytes is a pathological hallmark of psoriasis (26) . To examine the role of increased WT1 in the pathogenesis of PV, HaCaT cells were transfected with a WT1 overexpression plasmid or a control plasmid. The results of the western blot analysis demonstrated that the WT1 protein was successfully overexpressed in the WT1 expression plasmid-transfected cells (Fig. 3A) . A CCK-8 assay was performed to detect the proliferation of HaCaT cells. The results demonstrated that WT1 overexpression promoted the proliferation of HaCaT cells, particularly on days 4 and 5 following transfection (Fig. 3B ). Apoptosis analysis was subsequently performed. The results of the flow cytometry revealed that the proportion of Annexin-positive and propidium iodide-negative cells, which represent early apoptotic cells, was significantly decreased in the WT1 plasmid transfection group compared with the control group ( Fig. 3C and D) .
Knockdown of WT1 in keratinocytes inhibits proliferation and promotes apoptosis.
To further investigate the functional mechanism of WT1 in the pathogenesis of psoriasis, WT1 expression was knocked down in HaCaT cells using siRNA. The western blot analysis demonstrated that WT1 expression was significantly inhibited in the HaCaT cells transfected with WT1 siRNA compared with the negative control (Fig. 4A) . The transfected HaCaT cells were harvested at different time points for the CCK-8 assay. The results revealed that the proliferation ability of HaCaT cells was significantly decreased in the WT1 siRNA-transfected group compared with the control group (Fig. 4B ). In addition, the effect of WT1 knockdown on the apoptosis of HaCaT cells was detected by flow cytometry, and it was observed that the proportion of early apoptotic HaCaT cells was clearly increased in the WT1 siRNA-transfected group compared with the control siRNA group (Fig. 4C and D) .
WT1 expression is induced by proinflammatory factors.
It has been previously demonstrated that epidermal keratinocytes are responsive to immune cell-derived cytokines, including IFNs, IL-17 and IL-22, which are increased in the skin lesions of psoriasis (27) . To investigate the possible mechanisms associated with WT1 upregulation, HaCaT cells were stimulated with IL-17A, IFN-γ and IL-22. The results of RT-qPCR demonstrated that cytokines at higher concentrations, including IFN-γ, IL-17A and IL-22, promoted WT1 mRNA expression ( Fig. 5 ). These results indicated that the overexpression of WT1 may be due to the stimulation of proinflammatory factors in the local skin lesions of patients with psoriasis.
Discussion
Excessive proliferation and the abnormal apoptosis of keratinocytes serve an important role in the formation of psoriatic skin lesions (28) . Numerous cellular growth and metabolism-associated genes have been reported to be dysregulated in psoriasis skin lesions. The WT1 gene, frequently mutated in numerous cancer types, encodes transcription factor WT1, which regulates apoptosis and cell cycle progression (29) (30) (31) . In normal tissues, WT1 is an important regulator of cell growth and development (32) . Accumulating evidence has demonstrated that WT1 has an oncogenic function in tumorigenesis. WT1 knockdown by a WT1 antisense oligomer or WT1 specific short hairpin RNA inhibits the growth of cancer cells expressing WT1 (33) (34) (35) . Furthermore, overexpression of WT1 promotes cell growth, migration and invasion, and also inhibits cellular apoptosis under certain conditions (36) . However, there are no reports about WT1 mutation in psoriasis as yet, to the best of our knowledge, and there is poor understanding as to whether the dysregulation of WT1 is involved in the abnormal growth of keratinocytes observed in psoriasis.
The present study demonstrated that the expression of WT1 was low in normal skin and significantly upregulated in non-lesional and lesional skins from patients with psoriasis and the IMQ-induced psoriasis-like mouse model, suggesting that the alteration in WT1 gene expression may be involved in the early pathogenesis of psoriasis. The expression of WT1 was also positively correlated with PASI scores. In addition, the increased WT1 was limited to the epidermis of psoriatic skin, and it promoted the proliferation and inhibited the apoptosis of keratinocytes. WT1 is frequently involved in the regulation of cell growth and apoptosis through different target genes and signaling pathways, including C-myc (37), cellular tumor antigen p53-mediated cellular apoptosis (38) , and the mitogen activated protein kinase and Janus kinase-signal transducer and activator of transcription signaling pathways (39) . The majority of these target genes and signaling pathways are also involved in the pathogenesis of psoriasis (40) (41) (42) . A previous study reported that WT1 mediates keratinocyte growth factor (KGF) signaling in breast cancer cells, which promotes DNA synthesis, cell proliferation and migration (43) . KGF has been demonstrated to be upregulated in the upper dermis of psoriatic skin and its expression is correlated with keratinocyte growth (44) . Therefore, it was speculated that WT1 promotes keratinocyte proliferation by regulating the downstream KGF signaling pathway in patients with psoriasis.
Although the initial events triggering a psoriatic lesion remain unclear, pro-inflammatory cytokines, including IL-17A, IL-22 and IFN-γ, may drive keratinocyte hyperproliferation and aberrant differentiation in psoriasis. A previous study suggested that the average protein expression levels of IL-17A, IFN-γ and IL-22 in the cell culture supernatant of psoriatic CD4 + T cells are on the order of magnitude ng/ml (45) . In accordance with the literature (46) , HaCaT cells were with 0, 10, 20 or 50 ng/ml IL-17A, IFN-γ and IL-22 to examine their effect on the expression of WT1. It was demonstrated that these inflammatory cytokines were capable of inducing the overexpression of WT1 to varying degrees. It is widely for 24 h. The cells were collected and analyzed to detect the mRNA expression of WT1 (n=3). Compared with the control group, the mRNA expression of WT1 was increased in HaCaT cells stimulated with IL-17A (20 vs. 0 ng/ml, P= 0.003; 50 vs. 0 ng/ml, P= 0.0001), IFN-γ (20 vs. 0 ng/ml, P= 0.001; 50 vs. 0 ng/ml, P= 0.0001) and IL-22 (50 vs. 0 ng/ml, P= 0.011). All experiments were repeated a minimum of three times. The data are presented as the mean ± standard error of the mean. * P<0.05, ** P<0.01, *** P<0.001. One-way analysis of variance with Dunnett's post hoc test was used. WT1, Wilms' tumor 1; IFN, interferon; IL, interleukin.
accepted that the activation of nuclear factor (NF)-κB transcription factors, which are crucial mediators involved in the pathogenesis of psoriasis (47) , is a common downstream event following the stimulation of each of these cytokines (48) (49) (50) . The present results provide a possible novel mechanism through which inflammatory cytokines may stimulate the upregulation of WT1 in psoriatic skin. This process may be mediated by NF-κB signaling, which serves an essential role in cell cycle regulation in the pathogenesis of psoriasis.
In conclusion, the results of the present study demonstrated that inflammatory cytokines induced the overexpression of WT1, which mediated the excessive proliferation and inhibited the apoptosis of keratinocytes in psoriasis. To the best of our knowledge, the present study is the first to focus on the expression and role of WT1 in psoriasis, and a potential novel factor associated with the pathogenesis of psoriasis has been revealed. However, further research is required to confirm these findings and investigate the possible molecular mechanisms of WT1 in psoriasis.
